Contact this trialFirst, we need to learn more about you.
Antiretroviral
DTG/3TC for HIV-1 in Adolescents
Recruiting2 awardsPhase 3
Jacksonville, Florida
This trial tests a new two-drug pill for HIV-infected adolescents who haven't had treatment before. The pill combines DTG and 3TC, which work together to stop the virus from multiplying. The goal is to see if this simpler treatment is effective and safe over time. Dolutegravir (DTG) and lamivudine (3TC) have shown high efficacy and tolerability in both new and experienced HIV-positive patients, and are recommended as an alternative to more complex treatments to reduce long-term toxicity and costs.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service